DREAMM-2 demonstrates meaningful ORR with belantamab mafodotin in multiple myeloma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Treatment with the investigational single-agent belantamab mafodotin resulted in a 31% overall response rate with the 2.5 mg/kg regimen in patients with heavily pre-treated multiple myeloma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Joni D. Nelson, assistant director for the Office of Workforce Development at the MUSC Hollings Cancer Center, remembers the exact day a switch went off in her head and her career took a turn towards finding ways to improve public health.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login